Rinvoq

AbbVie Inc.🇺🇸 United States

FDA Page

Effective Date: Jun 30, 2026
Approval ID: 2966aec7-2ef0-923c-d8ff-fe1a957bf095
Products: 4 registered
Version: 101

Regulatory Information

Labeling Type

HUMAN PRESCRIPTION DRUG LABEL

Status

Approved

Full Title

These highlights do not include all the information needed to use RINVOQ / RINVOQ LQ safely and effectively. See full prescribing information for RINVOQ / RINVOQ LQ . RINVOQ (upadacitinib) extended-release tablets, for oral use RINVOQ LQ (upadacitinib) oral solution Initial U.S. Approval: 2019

Quick Stats

Total Products4

Labelers2

Label Sections39

Regulatory Agency

🇺🇸

U.S. Food and Drug Administration

United States

Data Sources & Disclaimer: Approval information is sourced from official FDA databases. This content is for informational purposes only and does not constitute medical or regulatory advice. Always refer to official FDA websites for the most current information.